OncoLize (2017) is based in Maastricht, The Netherlands.
We develop high performance oncology products for localized and slow delivery of drugs, making our products:
Our injectable drug depots are simple to use, effective, safe and affordable.
We are currently preparing advanced formulations for First-in-Human trials using a selection of well-known Chemo-drugs. This is based on preliminary PDX-mice studies with human Lung- and Pancreatic tumor grafts. These aggressive tumors were halted in their growth and reversed towards eradication of the tumor mass… even without the support of an intact immune system, which human patients normally do have!
Standard-of-care, generic Chemo was combined with the novelOCL-platformand injected intra-tumor but at much lower quantities than systemic dosing would dictate. No adverse reactions, neither locally or systemically were found.
What we have accomplished in other applications with our local drug delivery depots:
We have recently upgraded our injectable depot platform to the novelOCL-technology, which is i) faster to formulate and with a broader range of different types of drugs, ii) easier to use and to scale-up; iii) faster to obtain approvals with; and iv) less expensive towards advanced clinical trial development… compared to our previous platform InGell.
Surgeons and oncologists can inject these products straight into the tumor using standard-of-care guided catheters or long, thin needles.
Over time, the depot slowly dissolves, releasing the drug inside the tumor and keeping it there in sufficiently high concentrations… where it should be!
Our Team
CEO
The company was founded by Mike de Leeuw (CEO), who previously founded InGell Labs (2010), Branching Tree (2008) and DSM BioMedical (2005) and has a track record in re-structuring and re-financing other start-up’s within the controlled release/ biomedical materials space for drug delivery and cell therapy.
CTO
Mike is joined by dr.Leo de Leede (CTO), a long-time biopharmaceutical expert using polymer-enabled drug delivery in a.o. Organon/MSD – Yamanuchi/Astellas – OctoPlus/Dr.Reddy – Branching Tree/ InGell Labs.
CSO
As of April 2023 they are joined by Helena Kelly (CSO), full time professor at RCSI and the inventor of the licensed OncoLize Technology platform.
We switched to the OCL-platform, which is faster to formulate, easier to use in the clinic and far less costly to scale-up and approve (compared to our previous platform).
We have dedicated ourselves to develop products that deal with the urgent unmet needs for the ‘rare and deadly tumor diseases’.
Why?
We believe that everybody should have access to the best possible care for these aggressive tumor diseases.
We are certain that this can be done by localizing generic drugs and novel drugs alike, with much better effect, far less side-effects, and at much lower costs to the national healthcare systems.